ArticleHuman mutation2026
Development of a Multiplex Amplification System Using Oxford Nanopore Sequencing for STRs and InDels.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a Multiplex Amplification System Using Oxford Nanopore Sequencing for STRs and InDels.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanopore sequencing has emerged as a promising technology due to its real-time data acquisition, portability, and high throughput. However, the genotyping capabilities of the latest flow cell, R10.4.1, for short tandem repeats (STRs) remain insufficiently validated, and its accuracy in typing insertions or deletions (InDels) in earlier versions has been rarely investigated. To bridge these gaps, we developed the NanoID panel, a multiplex amplification system incorporating 29 autosomal STRs, 29 Y-chromosome STRs, 61 autosomal InDels, 2 Y-chromosome InDels, and amelogenin. We conducted genotyping on 112 unrelated individual samples and screened 114 loci with 100% accuracy. Subsequently, we evaluated these 114 loci for reproducibility, sensitivity, kinship inference, and species specificity. All loci were consistently and accurately genotyped across triplicate experiments. NanoID achieved an accuracy rate exceeding 99.12% (based on the 2-out-of-3 rule) when the DNA input was ≥ 50 pg. The combined power of discrimination and the cumulative probability of exclusion were 1 - 7.990 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.